Curium Pharma

Executive Summary

Curium Pharma is a global leader in nuclear medicine, with a heritage dating back to the 1960s and a current focus on oncology, particularly neuroendocrine and prostate cancers. The company develops, manufactures, and supplies radiopharmaceutical products for both diagnostics and therapy, serving over 14 million patients annually. Headquartered in Paris, France, Curium operates as a private entity with a broad portfolio of established and investigational agents. Its mission is to drive innovation in nuclear medicine to improve patient lives, leveraging vertical integration and global manufacturing capabilities. Strategically, Curium is advancing its pipeline with next-generation radiopharmaceuticals, including targeted alpha therapies and novel diagnostic tracers. The company is accelerating clinical programs for prostate-specific membrane antigen (PSMA) and somatostatin receptor-targeting agents, aiming to capture share in the rapidly growing theranostics market. With potential regulatory submissions on the horizon, Curium is well-positioned to benefit from increasing adoption of precision oncology. Its private status provides flexibility in long-term R&D investments, though near-term catalysts are tied to clinical data readouts and approval decisions.

Upcoming Catalysts (preview)

• Q1 2027FDA/EMA approval decision for 177Lu-PNT2002 (prostate cancer therapeutic)65% success
• Q3 2026Phase 3 data readout for 68Ga-PSMA-11 diagnostic in prostate cancer75% success
• H2 2026Strategic partnership or licensing deal for alpha-emitting radiopharmaceutical45% success